Healthcare / Diagnostics & ResearchKOSDAQ
$3975.00
-25.00 (-0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $261.3M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
66/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$51.2B
P/E
11.5x
↓EV/EBITDA
10.3x
↓ROE
14.6%
↑Gross Margin
61.5%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+25.5%
FCF CAGR
+21.4%
FCF margin
12.4%
FCF / Net income
0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.12B · net income $4.47B · FCF $1.88B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.12B | $15.12B | $10.51B | $8.23B | $7.64B |
| Net Income | $4.47B | $4.47B | $2.44B | $462.9M | $1.25B |
| EBITDA | $4.70B | $4.70B | $2.78B | $948.1M | $1.72B |
| EPS | 347.00 | 347.00 | 190.00 | 38.00 | 111.00 |
| Gross Margin | 61.5% | 61.5% | 59.7% | 49.6% | 60.5% |
| Operating Margin | 24.6% | 24.6% | 14.3% | 2.0% | 13.8% |
| Net Margin | 29.6% | 29.6% | 23.2% | 5.6% | 16.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 10.74 | 10.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.88B | $1.88B | $261.3M | $-1.34B | $1.05B |
| Returns | |||||
| ROE | 14.6% | 14.6% | 9.3% | 2.0% | 7.8% |
| Valuation | |||||
| P/E | 11.46 | 11.46 | 14.68 | 85.00 | 59.37 |
| EV/EBITDA | 10.32 | 10.32 | 11.96 | 39.86 | 42.23 |
| P/B | 1.67 | 1.67 | 1.37 | 1.67 | 4.65 |
| Growth & Yield | |||||
| Revenue Growth | 43.8% | 43.8% | 27.8% | 7.6% | — |
| EPS Growth | 82.6% | 82.6% | 400.0% | -65.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
0.5%
EPS terminal req.
$352.72
Spread vs growth
82.1%
5Y implied EPS CAGR
4.2%
EPS terminal req.
$426.79
Spread vs growth
78.4%
10Y implied EPS CAGR
7.1%
EPS terminal req.
$687.34
Spread vs growth
75.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.4%
Start / end P/E
17.2x → 11.5x
EPS bridge
190.00 → 347.00
Residual
-27.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.